Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | REN | P00797 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434349 | 0.91 | GPR119 (0.50) | RENPDE4BGPR119 | |
| SCHEMBL13434559 | 0.91 | GPR119 (0.50) | RENPDE4BGPR119 | |
| SCHEMBL13434290 | 0.91 | REN (0.47) | USP30RENPDE4BPDE4APDE4C | |
| SCHEMBL13434274 | 0.90 | GPR119 (0.47) | RENPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13434293 | 0.89 | REN (0.46) | USP30RENPDE4BPDE4APDE4C | |
| SCHEMBL13434291 | 0.89 | REN (0.48) | USP30RENPDE4BPDE4APDE4C | |
| SCHEMBL13434360 | 0.88 | REN (0.49) | USP30RENPDE4BPDE4APDE4C | |
| SCHEMBL3488998 | 0.88 | REN (0.49) | RENMEN1KMT2AL3MBTL1 | |
| SCHEMBL13434282 | 0.88 | REN (0.47) | USP30RENPDE4BPDE4APDE4C | |
| SCHEMBL13434242 | 0.87 | REN (0.52) | RENPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | USP30 3581/4885REN 1/4885MEN1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.